Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward C Keystone

Showing results (11-20 of 159) with videos related to

Pageof 16
Sort By:
Expert Opinion on Drug Safety|March 30, 2005
What to do with TNF failuresEdward C Keystone, Arthur Kavanaugh
Rheumatology (Oxford, England)|June 22, 2012
Rheumatoid arthritis: where are we now?Josef Smolen, Edward C Keystone
The Journal of Rheumatology. Supplement|June 11, 2009
Therapeutic targets for rheumatoid arthritisEdward C Keystone, Boulos Haraoui
Nature Reviews. Rheumatology|August 6, 2014
Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?Sabri Alsaeedi, Edward C Keystone
Rheumatology (Oxford, England)|June 22, 2012
Future of RA: building on what we know and tailoring treatmentJosef Smolen, Edward C Keystone
Nature Reviews. Rheumatology|February 13, 2013
Rational therapy in RA: Issues in implementing a treat-to-target approach in RAMarc D Cohen, Edward C Keystone
The Journal of Rheumatology. Supplement|May 4, 2010
Tumor necrosis factor and anti-tumor necrosis factor therapiesEdward C Keystone, Carl F Ware
Expert Review of Clinical Immunology|May 17, 2014
Intravenous golimumab in rheumatoid arthritisMarc D Cohen, Edward C Keystone
Clinical Rheumatology|December 11, 2008
Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysisShahin Jamal, Kaushik Patra, Edward C Keystone
The Journal of Rheumatology|April 5, 2011
Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonistsEdward C Keystone, Kim A Papp, Wendy Wobeser
Pageof 16

Showing results (11-20 of 159) with videos related to

Sort By:
Pageof 16
Expert Opinion on Drug Safety|March 30, 2005
What to do with TNF failuresEdward C Keystone, Arthur Kavanaugh
Rheumatology (Oxford, England)|June 22, 2012
Rheumatoid arthritis: where are we now?Josef Smolen, Edward C Keystone
The Journal of Rheumatology. Supplement|June 11, 2009
Therapeutic targets for rheumatoid arthritisEdward C Keystone, Boulos Haraoui
Nature Reviews. Rheumatology|August 6, 2014
Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?Sabri Alsaeedi, Edward C Keystone
Rheumatology (Oxford, England)|June 22, 2012
Future of RA: building on what we know and tailoring treatmentJosef Smolen, Edward C Keystone
Nature Reviews. Rheumatology|February 13, 2013
Rational therapy in RA: Issues in implementing a treat-to-target approach in RAMarc D Cohen, Edward C Keystone
The Journal of Rheumatology. Supplement|May 4, 2010
Tumor necrosis factor and anti-tumor necrosis factor therapiesEdward C Keystone, Carl F Ware
Expert Review of Clinical Immunology|May 17, 2014
Intravenous golimumab in rheumatoid arthritisMarc D Cohen, Edward C Keystone
Clinical Rheumatology|December 11, 2008
Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysisShahin Jamal, Kaushik Patra, Edward C Keystone
The Journal of Rheumatology|April 5, 2011
Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonistsEdward C Keystone, Kim A Papp, Wendy Wobeser
Pageof 16